Integrated Environmental Technologies 10-Q 12 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	9-May-14
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'INTEGRATED ENVIRONMENTAL TECHNOLOGIES, LTD.	'
Entity Central Index Key	'0001084031	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Document Period End Date	31-Mar-14	'
Document Type	'10-Q	'
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2014	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	230,778,176

Consolidated_Balance_Sheets_Un

Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash	$673,139	$1,049,399
Accounts receivable	21,271	28,250
Prepaid expenses	7,127	26,166
Inventory	131,051	126,952
Total current assets	832,588	1,230,767
Property and equipment, net	323,530	344,884
Total assets	1,156,118	1,575,651
Current liabilities:	'	'
Accounts payable	94,355	41,320
Accrued expenses	38,836	47,954
Customer deposits	38,109	38,109
Convertible debentures	25,000	25,000
Note payable	76,842	75,513
Total current liabilities	273,142	227,896
Convertible debentures	476,125	476,125
Note payable	26,829	46,546
Total liabilities	776,096	750,567
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Common stock, $.001 par value; 400,000,000 shares authorized; 230,778,176 and 229,971,926 shares issued and outstanding, respectively	230,778	229,972
Additional paid-in capital	20,147,095	20,075,764
Accumulated deficit	-19,997,851	-19,480,652
Total stockholders' equity	380,022	825,084
Total liabilities and stockholders' equity	$1,156,118	$1,575,651

Consolidated_Balance_Sheets_Un1

Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Balance Sheets [Abstract]	'	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	230,778,176	229,971,926
Common stock, shares outstanding	230,778,176	229,971,926

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Revenues:	'	'
Sales	$12,061	$22,330
Leasing and licensing fees	6,000	16,500
Total revenues	18,061	38,830
Cost of sales	4,245	5,375
Gross profit	13,816	33,455
Operating expenses:	'	'
General and administrative	297,477	278,354
Sales and marketing	160,367	105,107
Research and development	60,890	48,043
Total operating expenses	518,734	431,504
Loss from operations	-504,918	-398,049
Other income (expense):	'	'
Interest income	'	37
Interest expense	-12,281	-10,601
Total other income (expense)	-12,281	-10,564
Net loss	($517,199)	($408,613)
Net loss per share, basic and diluted	$0	$0
Weighted average shares outstanding, basic and diluted	230,424,912	156,334,611

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net loss	($517,199)	($408,613)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	21,354	37,836
Stock-based compensation expense	30,437	39,876
Changes in operating assets and liabilities:	'	'
Accounts receivable	4,478	5,957
Inventory	-4,099	-1,921
Prepaid expenses	19,039	10,208
Accounts payable	72,035	-9,745
Accrued expenses	-9,118	-8,938
Net cash used in operating activities	-383,073	-335,340
Cash flows from investing activity:	'	'
Purchase of equipment	'	-18,176
Cash flows from financing activities:	'	'
Proceeds from sale of common stock, net of offering costs	25,200	311,750
Repayment of note payable	-18,387	'
Net cash provided by financing activities	6,813	311,750
Decrease in cash	-376,260	-41,766
Cash - beginning of period	1,049,399	180,489
Cash - end of period	673,139	138,723
Supplemental disclosure of cash flow information:	'	'
Cash paid for interest	2,139	550
Cash paid for income taxes	700	'
Non-cash operating activity:	'	'
Issuance of 206,250 and 1,485,714 shares of common stock, respectively, as payment of director fees	$16,500	$52,000

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Statement of Cash Flows [Abstract]	'	'
Common stock issued as payment of director fees, shares	206,250	1,485,714

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Basis of Presentation [Abstract]	'
Basis of Presentation	'
	1.           Basis of Presentation
	The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.  The Company has incurred significant recurring operating losses and negative cash flows from operations.  The Company had working capital of $559,446 and an accumulated deficit of $19,997,851 as of March 31, 2014.  The Company also has no lending relationships with commercial banks and is dependent on the completion of financings involving the private placement of its securities in order to continue operations.  These factors raise substantial doubt about the Company’s ability to continue as a going concern.  The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	The Company does not anticipate establishing any lending relationships with commercial banks in the foreseeable future due to its limited operations and assets.  The Company continues to execute its strategy of selling anolyte and catholyte solutions and leasing its EcaFlo™ equipment to fund its operations and is focused on obtaining additional capital through the private placement of its securities.  The Company is pursuing potential equity and/or debt investors and, from time to time, has engaged placement agents to assist it in this initiative.  While the Company is pursuing the opportunities and actions described above, there can be no assurance that it will be successful in its efforts.  If the Company is unable to secure additional capital, it will explore other strategic alternatives, including, but not limited to, the sale of the Company.  Any additional equity financing may result in substantial dilution to the Company’s stockholders.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2014
Inventory [Abstract]	'
Inventory	'
	2.           Inventory
	As of March 31, 2014 and December 31, 2013, inventory consisted of parts and materials totaling $131,051 and $126,952, respectively.

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2014
Property and Equipment [Abstract]	'
Property and Equipment	'
	3.           Property and Equipment
	As of March 31, 2014 and December 31, 2013, property and equipment, on a net basis, consisted of the following (see note 7):
		March 31,			December 31,
		2014			2013
	Leasehold improvements	$	328,977		$	328,977
	Equipment		437,504			437,504
			766,481			766,481
	Less:  Accumulated depreciation		(442,951	)		(421,597	)
		$	323,530		$	344,884

Accrued_Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2014
Accrued Expenses [Abstract]	'
Accrued Expenses	'
	4.           Accrued Expenses
	As of March 31, 2014 and December 31, 2013, accrued expenses consisted of the following:
		March 31,		December 31,
		2014		2013
	Accrued interest	$	34,453	$	24,321
	Accrued auditing fees		2,750		22,000
	Accrued other expenses		1,633		1,633
		$	38,836	$	47,954

Customer_Deposits

Customer Deposits	3 Months Ended
	Mar. 31, 2014
Customer Deposits [Abstract]	'
Customer Deposits	'
	5.           Customer Deposits
	On March 29, 2011, the Company issued a credit to purchase equipment to a consultant in the amount of $36,109 as payment to the consultant for consulting services rendered to the Company.  The Company has recorded this amount as a customer deposit.
	Effective January 1, 2013, the Company entered into a license agreement with a third party related to the use by the third party of the Company’s United States Environmental Protection Agency (the “EPA”) registration for its anolyte solution.  The Company received a deposit of $2,000 pursuant to the terms of this agreement.

Convertible_Debentures

Convertible Debentures	3 Months Ended
	Mar. 31, 2014
Convertible Debentures [Abstract]	'
Convertible Debentures	'
	6.           Convertible Debentures
	April 2007 Convertible Debenture
	On April 26, 2007, in a private placement, the Company issued a convertible debenture to an individual accredited investor in the principal amount of $25,000.  This convertible debenture matured on January 2, 2009 and remains unpaid.  The convertible debenture accrues interest at a rate of 12% per annum and is convertible at any time into shares of the Company’s common stock at the option of the holder at a conversion price of $0.40 per share.  An aggregate of 62,500 shares of the Company’s common stock can be issued upon the conversion of the outstanding principal amount due on this convertible debenture at the current conversion price of $0.40 per share.
	During each of the three months ended March 31, 2014 and 2013, the Company recorded a total of $740 of interest expense related to this convertible debenture.  As of March 31, 2014 and December 31, 2013, the outstanding principal on this convertible debenture was $25,000 and the accrued and unpaid interest was $11,181 and $10,441, respectively.  The accrued and unpaid interest is included as a component of accrued expenses.
	Zanett Convertible Debentures
	On August 21, 2012, the Company issued to Zanett Opportunity Fund, Ltd. (“Zanett”) an 8% convertible debenture in the amount of $476,125 (the “Zanett August 2012 Debenture”).  In connection with this private placement, the Company refinanced an 8% convertible debenture, in the principal amount of $376,125, issued to Zanett on July 7, 2011 (the “Zanett July 2011 Debenture”) and refinanced an 8% convertible secured promissory note, in the principal amount of $100,000, issued to Zanett on September 23, 2011 (the “Zanett September 2011 Note”).  As a result of the issuance of the Zanett August 2012 Debenture, the Zanett July 2011 Debenture and the Zanett September 2011 Note were cancelled.
	The Zanett August 2012 Debenture has a three-year term maturing on August 21, 2015 and bears interest at a rate of 8% per annum.  Interest is payable in annual installments in cash or, at the option of the Company, in shares of the Company’s common stock.  If the Company elects to pay the interest in shares of its common stock, the number of shares issued as payment will be equal to the quotient of the unpaid interest divided by the market price of the Company’s common stock, as defined in the Zanett August 2012 Debenture.
	The entire principal amount of the Zanett August 2012 Debenture is convertible at any time into shares of the Company’s common stock at the option of the holder at a conversion price of $0.10 per share.  In addition, at the option of the Company, the entire principal amount of the Zanett August 2012 Debenture is convertible into shares of the Company’s common stock at $0.10 per share upon the occurrence of the merger or acquisition of the Company or if the average closing price of the Company’s common stock for any period of ten consecutive trading days is greater than or equal to $0.15 per share.  The quoted market price of the Company’s common stock on August 21, 2012 was $0.05 per share.  An aggregate of 4,761,250 shares of the Company’s common stock can be issued upon the conversion of the outstanding principal amount due on the Zanett August 2012 Debenture at the current conversion price of $0.10 per share.
	On August 22, 2013, the Company issued 400,947 shares of the Company’s common stock to Zanett as payment of $38,090 of accrued interest due on the Zanett August 2012 Debenture for the period commencing August 21, 2012 through August 20, 2013.  The number of shares of the Company’s common stock issued as payment of the accrued interest was calculated based on the market price of the Company’s common stock ($0.095 per share) as defined in the Zanett August 2012 Debenture.
	During the three months ended March 31, 2014 and 2013, the Company recorded $9,392 and $9,523, respectively, of interest expense related to the Zanett August 2012 Debenture.  As of March 31, 2014 and December 31, 2013, the outstanding principal on the Zanett August 2012 Debenture was $476,125 and the accrued and unpaid interest was $23,272 and $13,880, respectively.  The accrued and unpaid interest is included as a component of accrued expenses.

Note_Payable

Note Payable	3 Months Ended
	Mar. 31, 2014
Note Payable [Abstract]	'
Note Payable	'
	7.           Note Payable
	On June 17, 2013, the Company and Benchmark Performance Group, Inc. (“Benchmark”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”), whereby the Company purchased nineteen EcaFlo™ machines owned by Benchmark as well as the rights to the Excelyte™ trademark and certain other intangible assets.  The purchase price for the nineteen EcaFlo™ machines, the Excelyte™ trademark and other intangible assets was $190,000.
	The Company paid $38,000 in conjunction with the closing of the Asset Purchase Agreement and issued a promissory note with a principal balance of $152,000 (the “Benchmark Note”).  The Benchmark Note bears interest at a rate of 7% per annum and requires the Company to make twenty-four monthly payments of $6,805 commencing August 1, 2013.  The Benchmark Note is secured by the nineteen EcaFlo™ machines.
	For the three months ended March 31, 2014, the Company recorded $2,029 of interest expense related to the Benchmark Note.  As of March 31, 2014 and December 31, 2013, the outstanding principal on the Benchmark Note was $103,671 (current portion $76,842; long-term portion $26,829) and $122,059 (current portion $75,513; long-term portion $46,546), respectively.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity (Deficiency) [Abstract]	'
Stockholders' Equity (Deficiency)	'
	8.           Stockholders’ Equity
	Common Stock
	On January 8, 2014, the Company sold 350,000 shares of its common stock to an individual investor for an aggregate purchase price of $25,200, or $0.072 per share.
	On February 25, 2014, the Company issued an aggregate of 206,250 shares of its common stock, at a per share price of $0.08, as settlement of $16,500 of director fees due certain members of the Company’s board of directors for services rendered for the period commencing September 1, 2013 through December 31, 2013.  The quoted market price of the Company’s common stock on the date the issuance was approved by the Company’s board of directors was $0.08 per share.
	On March 14, 2014, the Company issued 250,000 shares of its common stock in connection with a consulting agreement with an unaffiliated third party for marketing services.  The total expense associated with the issuance of these shares was $20,000, representing the fair market value of the shares on the date of issuance ($0.08 per share).
	Stock Options
	The Company currently has two stock option/stock compensation plans in place:  the 2010 Stock Incentive Plan and the 2012 Equity Incentive Plan (collectively, the “Equity Incentive Plans”).
	The 2010 Stock Incentive Plan was approved by the stockholders in September 2010.  The Company had reserved for issuance an aggregate of 10,000,000 shares of common stock under the 2010 Stock Incentive Plan.  As of March 31, 2014, stock options to purchase 4,980,254 shares of the Company’s common stock were outstanding under the 2010 Stock Incentive Plan and 90,500 shares of the Company’s common stock had been issued under the 2010 Stock Incentive Plan.  As a result of the adoption of the Company’s 2012 Equity Incentive Plan, no further awards are permitted under the 2010 Stock Incentive Plan.
	The 2012 Equity Incentive Plan was approved by the stockholders in May 2012.  The Company has reserved for issuance an aggregate of 14,000,000 shares of common stock under the 2012 Stock Incentive Plan.  The 2012 Equity Incentive Plan is designed to encourage and enable employees and directors of the Company to acquire, or increase their holdings of, common stock and other proprietary interests in the Company.  It is intended to promote these individuals’ interests in the Company, thereby enhancing the efficiency, soundness, profitability, growth and stockholder value of the Company.  The 2012 Equity Incentive Plan provides for grants and/or awards in the form of incentive and non-qualified stock option grants, stock appreciation rights, restricted stock awards, performance share awards, phantom stock awards and dividend equivalent awards.  As of March 31, 2014, no grants or awards had been made under the 2012 Equity Incentive Plan.
	Common stock grants and stock option awards under the Equity Incentive Plans were granted or issued at prices as determined by the Company’s compensation committee; provided, however, that such prices were not less than the fair market value of the Company's common stock on the date of grant or issuance.  Stock options granted and outstanding to date consist of both incentive stock options and non-qualified stock options.
	A summary of stock option transactions under the Equity Incentive Plans during the three months ended March 31, 2014 is set forth below:
			Stock				Weighted				Aggregate
			Option				Average				Intrinsic
			Shares				Exercise				Value
							Price Per
							Common
							Share
	Outstanding at December 31, 2013			4,980,254			$	0.18			$	--
	Granted during the period			--				--				--
	Exercised during the period			--				--				--
	Terminated during the period			--				--				--
	Outstanding at March 31, 2014			4,980,254			$	0.18			$	--
	Available for purchase at March 31, 2014			3,313,586			$	0.12			$	--
	Available for purchase at December 31, 2013			3,313,586			$	0.12			$	--
	Information with respect to stock options outstanding and stock options exercisable as of March 31, 2014 is as follows:
					Stock Options Outstanding										Stock Options Exercisable
	Exercise				Number of				Weighted				Weighted		Number of		Weighted		Weighted
	Price				Shares				Average				Average		Shares		Average		Average
					Available				Exercise				Remaining		Available for		Exercise		Remaining
					Under				Price Per				Contractual		Purchase		Price Per		Contractual
					Outstanding				Common				Life (Years)		Under		Common		Life (Years)
					Stock				Share						Outstanding		Share
					Options										Stock
															Options
	$	0.08				300,000			$	0.08				0.1		300,000	$	0.08		0
	$	0.1				2,180,253			$	0.1				4.9		2,180,253	$	0.1		4.9
	$	0.2				833,333			$	0.2				8		833,333	$	0.2		8
	$	0.3				1,666,668			$	0.3				8		--		--		--
						4,980,254			$	0.18				6.2		3,313,586	$	0.12		5.2
	A summary of the non-vested shares subject to stock options granted under the Equity Incentive Plans as of March 31, 2014 is as follows:
			Stock				Weighted
			Option				Average
			Shares				Grant
							Date Fair
							Value
							Per Share
	Non-vested at December 31, 2013			1,666,668			$	0.05
	Granted during the period			--				--
	Vested during the period			--				--
	Terminated during the period			--				--
	Non-vested at March 31, 2014			1,666,668			$	0.05
	As of March 31, 2014, there was $22,014 of total unrecognized compensation cost related to non-vested, stock-based compensation arrangements granted under the Equity Incentive Plans.  That cost is expected to be recognized over a weighted average period of nine months.
	Warrants to Purchase Common Stock
	A summary of warrant transactions during the three months ended March 31, 2014 is as follows:
			Warrant				Weighted				Aggregate
			Shares				Average				Intrinsic
							Exercise				Value
							Price Per
							Common
							Share
	Outstanding at December 31, 2013			36,844,565			$	0.12			$	--
	Issued during the period			--				--				--
	Exercised during the period			--				--				--
Terminated during the period			--				--				--
Outstanding at March 31, 2014			36,844,565			$	0.12			$	--
Available for purchase at March 31, 2014			36,844,565			$	0.12			$	--
Available for purchase at December 31, 2013			36,844,565			$	0.12			$	--
Warrants issued by the Company contain exercise prices that were approved by the Company’s board of directors.  Such exercise prices are generally not less than the quoted market price of the Company's common stock on the date of issuance.  Warrants currently issued either vested immediately or over a period of up to three years and have a maximum term of ten years from the date of issuance.
Information with respect to warrants outstanding and warrants exercisable at March 31, 2014 is as follows:
				Warrants Outstanding										Warrants Exercisable
Range of				Number of				Weighted				Weighted		Number of		Weighted		Weighted
Exercise				Shares				Average				Average		Shares		Average		Average
Prices				Available				Remaining				Exercise		Available for		Remaining		Exercise
				Under				Contractual				Price Per		Purchase		Contractual		Price Per
				Outstanding				Life (Years)				Common		Under		Life (Years)		Common
				Warrants								Share		Outstanding				Share
														Warrants
$	0.03 - 0.04				1,151,567				2.8			$	0.04		1,151,567		2.8	$	0.04
$	0.07 - 0.10				23,056,061				3.7			$	0.09		23,056,061		3.7	$	0.09
$	0.2				12,636,937				1			$	0.2		12,636,937		1	$	0.2
					36,844,565				2.7			$	0.13		36,844,565		2.7	$	0.13
As of March 31, 2014, there were no non-vested shares subject to warrants and no unrecognized compensation cost related to warrants.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2014
Stock-Based Compensation [Abstract]	'
Stock-Based Compensation	'
	9.           Stock-Based Compensation
	During the three months ended March 31, 2014 and 2013, the Company recorded stock-based compensation expense as follows:
		Three
		Months Ended
		March 31,
		2014		2013
	General and administrative	$	26,837	$	36,276
	Sales and marketing		2,520		2,520
	Research and development		1,080		1,080
	Total	$	30,437	$	39,876
	For the three months ended March 31, 2014 and 2013, the Company recorded stock-based compensation expense related to stock options granted to employees and directors of $10,437 and $11,985, respectively.  For the three months ended March 31, 2014 and 2013, the Company recorded stock-based compensation expense related to common stock and warrants granted to non-employees of $20,000 and $27,891, respectively.

Net_Loss_Per_Common_Share

Net Loss Per Common Share	3 Months Ended
	Mar. 31, 2014
Net Loss Per Common Share [Abstract]	'
Net Loss Per Common Share	'
	10.         Net Loss Per Common Share
	Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period.  Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not deemed to be anti-dilutive.  The dilutive effect of the outstanding stock options and warrants is computed using the treasury stock method.
	For the three months ended March 31, 2014, diluted net loss per share did not include the effect of 4,980,254 shares of common stock issuable upon the exercise of outstanding stock options, 36,844,565 shares of common stock issuable upon the exercise of outstanding warrants and 4,823,750 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive.
	For the three months ended March 31, 2013, diluted net loss per share did not include the effect of 5,813,587 shares of common stock issuable upon the exercise of outstanding stock options, 46,127,998 shares of common stock issuable upon the exercise of outstanding warrants and 4,823,750 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
	11.           Commitments and Contingencies
	The Company entered into a lease agreement for its premises located in Little River, South Carolina on January 1, 2006.  The lease agreement had an original term of three years.  In January 2009, the Company agreed to renew the lease agreement for a term of five years, ending on December 31, 2013, at $71,291 per year.  The renewal term contained the same covenants, conditions, and provisions as provided in the original lease agreement.  The Company is currently leasing the premises on a month-to-month basis.

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2014
Accrued Expenses [Abstract]	'
Components of accrued expenses	'
		March 31,		December 31,
		2014		2013
	Accrued interest	$	34,453	$	24,321
	Accrued auditing fees		2,750		22,000
	Accrued other expenses		1,633		1,633
		$	38,836	$	47,954

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2014
Stock Options [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Schedule of s stock option and warrants transactions under the Equity Incentive Plan	'
			Stock				Weighted				Aggregate
			Option				Average				Intrinsic
			Shares				Exercise				Value
							Price Per
							Common
							Share
	Outstanding at December 31, 2013			4,980,254			$	0.18			$	--
	Granted during the period			--				--				--
	Exercised during the period			--				--				--
	Terminated during the period			--				--				--
	Outstanding at March 31, 2014			4,980,254			$	0.18			$	--
	Available for purchase at March 31, 2014			3,313,586			$	0.12			$	--
	Available for purchase at December 31, 2013			3,313,586			$	0.12			$	--
Schedule of share-based compensation, outstanding options and options exercisable	'
					Stock Options Outstanding										Stock Options Exercisable
	Exercise				Number of				Weighted				Weighted		Number of		Weighted		Weighted
	Price				Shares				Average				Average		Shares		Average		Average
					Available				Exercise				Remaining		Available for		Exercise		Remaining
					Under				Price Per				Contractual		Purchase		Price Per		Contractual
					Outstanding				Common				Life (Years)		Under		Common		Life (Years)
					Stock				Share						Outstanding		Share
					Options										Stock
															Options
	$	0.08				300,000			$	0.08				0.1		300,000	$	0.08		0
	$	0.1				2,180,253			$	0.1				4.9		2,180,253	$	0.1		4.9
	$	0.2				833,333			$	0.2				8		833,333	$	0.2		8
	$	0.3				1,666,668			$	0.3				8		--		--		--
						4,980,254			$	0.18				6.2		3,313,586	$	0.12		5.2
Schedule of nonvested share activity	'
			Stock				Weighted
			Option				Average
			Shares				Grant
							Date Fair
							Value
							Per Share
	Non-vested at December 31, 2013			1,666,668			$	0.05
	Granted during the period			--				--
	Vested during the period			--				--
	Terminated during the period			--				--
	Non-vested at March 31, 2014			1,666,668			$	0.05
Warrants [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Schedule of s stock option and warrants transactions under the Equity Incentive Plan	'
			Warrant				Weighted				Aggregate
			Shares				Average				Intrinsic
							Exercise				Value
							Price Per
							Common
							Share
	Outstanding at December 31, 2013			36,844,565			$	0.12			$	--
	Issued during the period			--				--				--
	Exercised during the period			--				--				--
	Terminated during the period			--				--				--
	Outstanding at March 31, 2014			36,844,565			$	0.12			$	--
	Available for purchase at March 31, 2014			36,844,565			$	0.12			$	--
	Available for purchase at December 31, 2013			36,844,565			$	0.12			$	--
Schedule of share-based compensation, outstanding options and options exercisable	'
					Warrants Outstanding										Warrants Exercisable
	Range of				Number of				Weighted				Weighted		Number of		Weighted		Weighted
	Exercise				Shares				Average				Average		Shares		Average		Average
	Prices				Available				Remaining				Exercise		Available for		Remaining		Exercise
					Under				Contractual				Price Per		Purchase		Contractual		Price Per
					Outstanding				Life (Years)				Common		Under		Life (Years)		Common
					Warrants								Share		Outstanding				Share
															Warrants
	$	0.03 - 0.04				1,151,567				2.8			$	0.04		1,151,567		2.8	$	0.04
	$	0.07 - 0.10				23,056,061				3.7			$	0.09		23,056,061		3.7	$	0.09
	$	0.2				12,636,937				1			$	0.2		12,636,937		1	$	0.2
						36,844,565				2.7			$	0.13		36,844,565		2.7	$	0.13

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2014
Stock-Based Compensation [Abstract]	'
Schedule of recognized stock-based compensation expense	'
		Three
		Months Ended
		March 31,
		2014		2013
	General and administrative	$	26,837	$	36,276
	Sales and marketing		2,520		2,520
	Research and development		1,080		1,080
	Total	$	30,437	$	39,876

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2014
Property and Equipment [Abstract]	'
Components of property and equipment, on a net basis	'
		March 31,			December 31,
		2014			2013
	Leasehold improvements	$	328,977		$	328,977
	Equipment		437,504			437,504
			766,481			766,481
	Less:  Accumulated depreciation		(442,951	)		(421,597	)
		$	323,530		$	344,884

Basis_of_Presentation_Details

Basis of Presentation (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Basis of Presentation (Textual)	'	'
Working capital deficiency	$559,446	'
Accumulated deficit	($19,997,851)	($19,480,652)

Inventory_Details

Inventory (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Inventory (Textual)	'	'
Parts and materials	$131,051	$126,952

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Components of property and equipment, on a net basis	'	'
Leasehold improvements	$328,977	$328,977
Equipment	437,504	437,504
Property and equipment, Gross	766,481	766,481
Less: Accumulated depreciation	-442,951	-421,597
Property and equipment, net	$323,530	$344,884

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Components of accrued expenses	'	'
Accrued interest	$34,453	$24,321
Accrued auditing fees	2,750	22,000
Accrued other expenses	1,633	1,633
Accrued liabilities, total	$38,836	$47,954

Customer_Deposits_Details

Customer Deposits (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Customer Deposits (Textual)	'	'	'
Customer deposits	$38,109	$38,109	$36,109
Deposit received	$2,000	'	'

Convertible_Debentures_Details

Convertible Debentures (Details) (USD $)

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Apr. 26, 2007

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Aug. 22, 2013

Aug. 21, 2012

Mar. 31, 2014

Mar. 31, 2013

Aug. 20, 2013

Dec. 31, 2013

Jul. 07, 2011

Sep. 23, 2011

April 2007 Convertible Debenture [Member]

April 2007 Convertible Debenture [Member]

April 2007 Convertible Debenture [Member]

April 2007 Convertible Debenture [Member]

Zanett August 2012 Debenture [Member]

Zanett August 2012 Debenture [Member]

Zanett August 2012 Debenture [Member]

Zanett August 2012 Debenture [Member]

Zanett August 2012 Debenture [Member]

Zanett August 2012 Debenture [Member]

Zanett July 2011 Debenture [Member]

Zanett September 2011 Note [Member]

Convertible Debentures (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible debenture issued, Principal amount

'

'

'

$25,000

'

'

'

'

$476,125

'

'

'

'

$376,125

$100,000

Convertible debenture, Maturity Date

'

'

'

2-Jan-09

'

'

'

'

21-Aug-15

'

'

'

'

'

'

Convertible debenture, Interest Rate

'

'

'

12.00%

'

'

'

'

8.00%

'

'

'

'

8.00%

8.00%

Interest expense

12,281

10,601

'

'

740

740

'

'

'

9,392

9,523

'

'

'

'

Common stock issued pursuant to the Secured Notes

'

'

'

'

'

'

'

'

4,761,250

'

'

'

'

'

'

Outstanding principal

476,125

'

476,125

'

25,000

'

25,000

'

'

476,125

'

'

476,125

'

'

Accrued and unpaid interest on convertible debt

'

'

'

'

11,181

'

10,441

38,090

'

23,272

'

'

13,880

'

'

Promissory Note Convertible debenture, Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

Convertible debenture, Conversion Price

'

'

'

$0.40

'

'

'

'

$0.10

'

'

'

'

'

'

Common stock issued as payment on principal and interest on convertible debentures, shares

'

'

'

62,500

'

'

'

'

'

'

'

'

'

'

'

Condition for conversion of debt amount to common stock

'

'

'

'

'

'

'

'

'

'The occurrence of the merger or acquisition of the Company or if the average closing price of the Company's common stock for any period of ten consecutive trading days is greater than or equal to $0.15 per share.

'

'

'

'

'

Convertible debenture maturity term

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

Common stock market price

'

'

'

'

'

'

'

$0.10

$0.05

'

'

$0.10

'

'

'

Common stock issued for payment of interest, shares

'

'

'

'

'

'

'

400,947

'

'

'

'

'

'

'

Accrued interest

'

'

'

'

'

'

'

'

'

'

'

$38,090

'

'

'

Note_Payable_Details

Note Payable (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
	Machine
Note Payable (Textual)	'	'
Notes payable current portion	$76,842	$75,513
Note payable long term portion	26,829	46,546
Asset Purchase Agreement [Member]	'	'
Note Payable (Textual)	'	'
Number of machines purchase agreement	19	'
Purchase price of asset	190,000	'
Payment in closing of asset purchase agreement	38,000	'
Issuance of promissory note principal balance	152,000	'
Convertible promissory notes, interest percentage	7.00%	'
Convertible promissory notes, maturity date	1-Aug-13	'
Periodic payment	6,805	'
Description of payment term	'Twenty-four monthly payments.	'
Interest expense	2,029	'
Notes Payable	103,671	122,059
Notes payable current portion	76,842	75,513
Note payable long term portion	$26,829	$46,546

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2012
Stock Options [Member]	'	'
Summary of stock option and warrant transactions	'	'
Outstanding, Number, Beginning Balance	4,980,254	'
Granted during the period, Shares	'	'
Exercised during the period, Shares	'	'
Terminated during the period, Shares	'	'
Outstanding shares, Ending balance	4,980,254	'
Available for purchase, Ending Balance	3,313,586	1,806,793
Available for purchase, Beginning Balance	3,313,586	1,806,793
Outstanding, Weighted Average Exercise Price, Beginning Balance	$0.18	'
Grants in Period, Weighted Average Exercise Price	'	'
Exercises in Period, Weighted Average Exercise Price	'	'
Terminated, Weighted Average Exercise Price	'	'
Outstanding, Weighted Average Exercise Price, Ending balance	$0.18	'
Available for purchase, Weighted Average Exercise Price, Ending balance	$0.12	$0.10
Available for purchase, Weighted Average Exercise Price, Beginning balance	$0.12	$0.10
Outstanding, Intrinsic Value	'	'
Granted Aggregate Intrinsic Value	'	'
Exercised Aggregate Intrinsic Value	'	'
Terminated Aggregate Intrinsic Value	'	'
Outstanding, Aggregate Intrinsic Value, Ending balance	'	'
Available for purchase, Intrinsic Value, Ending Balance	'	'
Available for purchase, Intrinsic Value, Beginning Balance	'	'
Warrants [Member]	'	'
Summary of stock option and warrant transactions	'	'
Outstanding, Number, Beginning Balance	36,844,565	'
Granted during the period, Shares	'	'
Exercised during the period, Shares	'	'
Terminated during the period, Shares	'	'
Outstanding shares, Ending balance	36,844,565	'
Available for purchase, Ending Balance	36,844,565	45,852,998
Available for purchase, Beginning Balance	36,844,565	45,852,998
Outstanding, Weighted Average Exercise Price, Beginning Balance	$0.12	'
Grants in Period, Weighted Average Exercise Price	'	'
Exercises in Period, Weighted Average Exercise Price	'	'
Terminated, Weighted Average Exercise Price	'	'
Outstanding, Weighted Average Exercise Price, Ending balance	$0.12	'
Available for purchase, Weighted Average Exercise Price, Ending balance	$0.12	$0.17
Available for purchase, Weighted Average Exercise Price, Beginning balance	$0.12	$0.17
Outstanding, Intrinsic Value	'	'
Granted Aggregate Intrinsic Value	'	'
Exercised Aggregate Intrinsic Value	'	'
Terminated Aggregate Intrinsic Value	'	'
Outstanding, Aggregate Intrinsic Value, Ending balance	'	'
Available for purchase, Intrinsic Value, Ending Balance	'	'
Available for purchase, Intrinsic Value, Beginning Balance	'	'

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Employee Stock Option [Member]	'	'
Summary of stock option and warrant transactions	'	'
Stock Options Outstanding, Number of Shares Available under outstanding Option/warrant	4,980,254	4,980,254
Stock Options Outstanding, Weighted Average Exercise Price Per Common Share	$0.18	$0.18
Stock Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'6 years 2 months 12 days	'
Stock Options Exercisable, Number of Shares Available for Purchase Under Outstanding stock	3,313,586	'
Stock Options Exercisable, Weighted Average Exercise Price Per Common Share	$0.12	'
Stock Options Exercisable, Weighted Average Remaining Contractual Life (Years)	'5 years 2 months 12 days	'
Employee Stock Option [Member] | Range 1 [Member]	'	'
Summary of stock option and warrant transactions	'	'
Range of exercise prices	$0.08	'
Stock Options Outstanding, Number of Shares Available under outstanding Option/warrant	300,000	'
Stock Options Outstanding, Weighted Average Exercise Price Per Common Share	$0.08	'
Stock Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'1 month 6 days	'
Stock Options Exercisable, Number of Shares Available for Purchase Under Outstanding stock	300,000	'
Stock Options Exercisable, Weighted Average Exercise Price Per Common Share	$0.08	'
Stock Options Exercisable, Weighted Average Remaining Contractual Life (Years)	'0 years	'
Employee Stock Option [Member] | Range 2 [Member]	'	'
Summary of stock option and warrant transactions	'	'
Range of exercise prices	$0.10	'
Stock Options Outstanding, Number of Shares Available under outstanding Option/warrant	2,180,253	'
Stock Options Outstanding, Weighted Average Exercise Price Per Common Share	$0.10	'
Stock Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'4 years 10 months 24 days	'
Stock Options Exercisable, Number of Shares Available for Purchase Under Outstanding stock	2,180,253	'
Stock Options Exercisable, Weighted Average Exercise Price Per Common Share	$0.10	'
Stock Options Exercisable, Weighted Average Remaining Contractual Life (Years)	'4 years 10 months 24 days	'
Employee Stock Option [Member] | Range 3 [Member]	'	'
Summary of stock option and warrant transactions	'	'
Range of exercise prices	$0.20	'
Stock Options Outstanding, Number of Shares Available under outstanding Option/warrant	833,333	'
Stock Options Outstanding, Weighted Average Exercise Price Per Common Share	$0.20	'
Stock Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'8 years	'
Stock Options Exercisable, Number of Shares Available for Purchase Under Outstanding stock	833,333	'
Stock Options Exercisable, Weighted Average Exercise Price Per Common Share	$0.20	'
Stock Options Exercisable, Weighted Average Remaining Contractual Life (Years)	'8 years	'
Employee Stock Option [Member] | Range 4 [Member]	'	'
Summary of stock option and warrant transactions	'	'
Range of exercise prices	$0.30	'
Stock Options Outstanding, Number of Shares Available under outstanding Option/warrant	1,666,668	'
Stock Options Outstanding, Weighted Average Exercise Price Per Common Share	$0.30	'
Stock Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'8 years	'
Stock Options Exercisable, Number of Shares Available for Purchase Under Outstanding stock	'	'
Stock Options Exercisable, Weighted Average Exercise Price Per Common Share	'	'
Warrant [Member]	'	'
Summary of stock option and warrant transactions	'	'
Stock Options Outstanding, Number of Shares Available under outstanding Option/warrant	36,844,565	36,844,565
Stock Options Outstanding, Weighted Average Exercise Price Per Common Share	$0.12	$0.12
Stock Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'2 years 8 months 12 days	'
Stock Options Exercisable, Number of Shares Available for Purchase Under Outstanding stock	36,844,565	'
Stock Options Exercisable, Weighted Average Exercise Price Per Common Share	$0.13	'
Stock Options Exercisable, Weighted Average Remaining Contractual Life (Years)	'2 years 8 months 12 days	'
Warrant [Member] | Range 1 [Member]	'	'
Summary of stock option and warrant transactions	'	'
Range of exercise prices, Lower limit	$0.03	'
Range of exercise prices, Upper limit	$0.04	'
Stock Options Outstanding, Number of Shares Available under outstanding Option/warrant	1,151,567	'
Stock Options Outstanding, Weighted Average Exercise Price Per Common Share	$0.04	'
Stock Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'2 years 9 months 18 days	'
Stock Options Exercisable, Number of Shares Available for Purchase Under Outstanding stock	1,151,567	'
Stock Options Exercisable, Weighted Average Exercise Price Per Common Share	$0.04	'
Stock Options Exercisable, Weighted Average Remaining Contractual Life (Years)	'2 years 9 months 18 days	'
Warrant [Member] | Range 2 [Member]	'	'
Summary of stock option and warrant transactions	'	'
Range of exercise prices, Lower limit	$0.07	'
Range of exercise prices, Upper limit	$0.10	'
Stock Options Outstanding, Number of Shares Available under outstanding Option/warrant	23,056,061	'
Stock Options Outstanding, Weighted Average Exercise Price Per Common Share	$0.09	'
Stock Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'3 years 8 months 12 days	'
Stock Options Exercisable, Number of Shares Available for Purchase Under Outstanding stock	23,056,061	'
Stock Options Exercisable, Weighted Average Exercise Price Per Common Share	$0.09	'
Stock Options Exercisable, Weighted Average Remaining Contractual Life (Years)	'3 years 8 months 12 days	'
Warrant [Member] | Range 3 [Member]	'	'
Summary of stock option and warrant transactions	'	'
Range of exercise prices	$0.20	'
Stock Options Outstanding, Number of Shares Available under outstanding Option/warrant	2,622,500	'
Stock Options Outstanding, Weighted Average Exercise Price Per Common Share	$0.50	'
Stock Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'1 year	'
Stock Options Exercisable, Number of Shares Available for Purchase Under Outstanding stock	12,636,937	'
Stock Options Exercisable, Weighted Average Exercise Price Per Common Share	$0.20	'
Stock Options Exercisable, Weighted Average Remaining Contractual Life (Years)	'1 year	'

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2) (Employee Stock Option [Member], USD $)	3 Months Ended
	Mar. 31, 2014
Employee Stock Option [Member]	'
Summary of the non-vested shares subject to options granted/Warrant	'
Nonvested, Number, Beginning Balance	1,666,668
Granted during the period	'
Vested during the period	'
Terminated during the period	'
Non-vested Balance	1,666,668
Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance	$0.05
Weighted Average Grant Date Fair Value Per Share, Granted	'
Weighted Average Grant Date Fair Value Per Share, Vested	'
Weighted Average Grant Date Fair Value Per Share, Terminated	'
Weighted Average Grant Date Fair Value Per Share, Ending Balance	$0.05

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)	0 Months Ended		3 Months Ended	0 Months Ended			3 Months Ended
	Mar. 14, 2014	Feb. 25, 2014	Mar. 31, 2014	Jan. 08, 2014	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2014
				Individual Investor [Member]	Warrants [Member]	Warrants [Member]	2010 Stock Incentive Plan [Member]	2012 Equity Incentive Plan [Member]
Stockholders Deficiency (Textual)	'	'	'	'	'	'	'	'
Common Stock Reserved	'	'	'	'	'	'	10,000,000	14,000,000
Common Stock Issued under incentive plan	'	'	'	'	'	'	90,500	'
Outstanding shares under stock option plan	'	'	'	'	36,844,565	36,844,565	5,813,587	'
Common stock purchase due to issuance of warrants	'	'	'	'	250,000	'	'	'
Exercise price of shares	$0.08	'	'	'	'	'	'	'
Total unrecognized compensation cost related to non-vested stock-based compensation arrangements	'	'	'	'	'	'	'	$22,014
Cost expected to be recognized over weighted average period	'	'	'	'	'	'	'	'9 months
Common stock share sold	'	'	'	350,000	'	'	'	'
Shares issued, price per share	'	'	'	$0.07	'	'	'	'
Aggregate purchase price of common stock sold	'	'	'	25,200	'	'	'	'
Quoted market price of common stock	'	$0.08	'	'	'	'	'	'
Common stock issued under consulting agreement	250,000	'	'	'	'	'	'	'
Total expense associated with issuance of shares	20,000	'	'	'	'	'	'	'
Common stock unit sold	'	206,250	'	'	'	'	'	'
Common stock issued for settlement of outstanding amount owed for services, amount	'	$16,500	'	'	'	'	'	'
Aggregate purchase price of common stock, per share	'	$0.08	'	'	'	'	'	'
Minimum vesting period of warrant	'	'	'3 years	'	'	'	'	'
Maximum vesting period of warrant	'	'	'10 years	'	'	'	'	'

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Schedule of recognized stock-based compensation expense	'	'
Stock-based compensation expense	$30,437	$39,876
General and administrative [Member]	'	'
Schedule of recognized stock-based compensation expense	'	'
Stock-based compensation expense	26,837	36,276
Sales and marketing [Member]	'	'
Schedule of recognized stock-based compensation expense	'	'
Stock-based compensation expense	2,520	2,520
Research and development [Member]	'	'
Schedule of recognized stock-based compensation expense	'	'
Stock-based compensation expense	$1,080	$1,080

StockBased_Compensation_Detail1

Stock-Based Compensation (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Employees and directors [Member]	'	'
Stock Based Compensation (Textual)	'	'
Stock based compensation expense related to stock options	$10,437	$11,985
Non-employees [Member]	'	'
Stock Based Compensation (Textual)	'	'
Stock based compensation expense related to stock options	$20,000	$27,891

Net_Loss_Per_Common_Share_Deta

Net Loss Per Common Share (Details)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Stock Options [Member]	'	'
Net Loss Per Common Share (Textual)	'	'
Anti-dilutive securities	4,980,254	5,813,587
Warrants [Member]	'	'
Net Loss Per Common Share (Textual)	'	'
Anti-dilutive securities	36,844,565	46,127,998
Convertible debt [Member]	'	'
Net Loss Per Common Share (Textual)	'	'
Anti-dilutive securities	4,823,750	4,823,750

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	0 Months Ended	1 Months Ended
	Jan. 01, 2006	Jan. 31, 2009
Commitments and Contingencies (Textual)	'	'
Original term of lease	'3 years	'
Renewed lease agreement expiration period	'	'5 years
Lease termination date	'	31-Dec-13
Rental lease expense, per year	'	$71,291